Yet another aspect of the invention is to provide a method for treating patients not responsive to a PDE-5 inhibitor alone, the method including administering both PT-141 and a PDE-5 inhibitor, wherein the PDE-5 inhibitor is administered prior to administration of PT-141
This term is very subjective and dependent on the type of light source used
Complete clearance typically occurs four to five weeks after your final injection, though trace amounts may linger slightly longer in some individuals
Ammon HPT, Klumpp S, Fu A, Verspohl EJ, Jaeschke H, Wendel A, et al
Zdzieblik, D., et al
The Association for Accessible Medicines (AAM) argued that, unlike guidance from European regulators, FDA's guidance lacked clarity and detail